RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All FDA (CBER) updates
FDA (CBER)
GUIDANCE DRAFT
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry
Published: 9/24/2025Detected: 3/25/2026

Summary preview

Clarifies and proposes how FDA CBER intends to apply expedited development and review programs to regenerative medicine therapies intended for serious conditions, including more structured pathways to interact with FDA.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
manufacturing
quality
clinical
safety
labeling
rare_diseases
#CBER
#regenerative medicine therapies
#expedited programs
#serious conditions
#clinical evidence

Official Source Document
Source Verified

Access the original document directly from FDA CBER.

View Official Document

More from FDA (CBER)

  • Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry11/3/2026
  • Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
  • Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
  • Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
  • Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026

Get FDA (CBER) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.